Table 2 represents the odds ratio estimate of the likelihood of receiving adjuvant chemotherapy. Factors that reached significance for adjuvant chemotherapy use includes age 18-40 years, poor and ...

Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy. We conducted a phase 3, ...

The Neotorch randomized phase III clinical trial was designed to evaluate whether the addition of perioperative toripalimab [programmed cell death 1 (PD-1) inhibitor] to platinum-based chemotherapy ...

Low dose (metronomic) chemotherapy is a condensed, lower dose form of chemotherapy that is given on a more frequent schedule than traditional regimens. Traditional chemotherapies are usually given at ...